Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Announces Positive TERN-701 Data at ASH Annual Meeting
Summary
On November 3, 2025, Terns Pharmaceuticals, Inc. announced that updated data from the Phase 1 CARDINAL trial of TERN-701 in patients with relapsed/refractory CML has been selected for oral presentation at the 67th ASH Annual Meeting on December 8, 2025. The data, as of June 30, 2025, showed a 75% major molecular response rate by 24 weeks among 32 efficacy-evaluable patients. TERN-701 demonstrated high response rates across difficult-to-treat subgroups and a favorable safety profile with no dose-limiting toxicities observed. The company will host an investor call following the presentation to discuss these results.
Profitelligence Alerts
Get alerts for TERN
Be first to know when Terns Pharmaceuticals Inc. files with the SEC.
Filing Categories
Advertisement
About Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the discovery and development of novel therapeutic candidates targeting liver disease and oncology. Its primary function is to advance its pipeline of clinical and preclinical drug candidates that address significant unmet medical needs. One of the company's main focuses is on non-alcoholic steatohepatitis (NASH), a progressive liver disease. Through innovative approaches, Terns Pharmaceuticals explores various mechanisms to treat NASH, including small molecules designed to reduce liver inflammation and fibrosis. Beyond liver disease, the company is expanding its platform to include oncology, diversifying its impact in the healthcare industry. As a key player in the biopharmaceutical sector, Terns Pharmaceuticals Inc. contributes to the growing landscape of targeted therapies. With a dedicated emphasis on research and development, the company plays an essential role in pushing the boundaries of treatment options, potentially transforming the management of chronic liver diseases and cancer.
Official SEC Documents
Advertisement